OPEXA THERAPEUTICS, INC. (NASDAQ:OPXA) Files An 8-K Results of Operations and Financial Condition

OPEXA THERAPEUTICS, INC. (NASDAQ:OPXA) Files An 8-K Results of Operations and Financial Condition

Story continues below

Item 2.02. Results of Operations and Financial Condition.

On May 12, 2017, Opexa Therapeutics, Inc. filed its Quarterly
Report on Form 10-Q for the quarter ended March 31, 2017 and
announced its results of operations in a press release. A copy of
the press release announcing the results is furnished as Exhibit
99.1 to this Current Report on Form 8-K and is incorporated
herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Press release issued by Opexa Therapeutics, Inc. on May
12, 2017.
The information in Item 2.02 of this Current Report on Form 8-K,
including Exhibit99.1, shall not be deemed filed for the purposes
of Section 18 of the Securities Exchange Act of 1934 or otherwise
subject to the liabilities under that Section, nor be deemed to
be incorporated by reference into the filings of the registrant
under the Securities Act of 1933.


Opexa Therapeutics, Inc. (Opexa) is a biopharmaceutical company. The Company is engaged in the development of a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on its T-cell technology. The Company’s product candidates include Tcelna and OPX-212. Tcelna is an autologous T-cell immunotherapy that is being developed for the treatment of secondary progressive MS (SPMS) and is tailored to each patient’s immune response profile to myelin. Tcelna is designed to reduce the number and/or functional activity of specific subsets of myelin-reactive T-cells (MRTCs) known to attack myelin. Tcelna is manufactured using its method for the production of an autologous T-cell product. In addition to the ongoing clinical development of Tcelna, the Company is developing OPX-212 as an autologous T-cell immunotherapy for the treatment of NMO.


OPEXA THERAPEUTICS, INC. (NASDAQ:OPXA) closed its last trading session down -0.010 at 0.600 with 38,385 shares trading hands.

An ad to help with our costs